Opendata, web and dolomites

ImplantFreeSpine

World’s first complete motion-preservation 'Implant-less' surgical correction for Scoliosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImplantFreeSpine project word cloud

Explore the words cloud of the ImplantFreeSpine project. It provides you a very rough idea of what is the project "ImplantFreeSpine" about.

conduct    planning    hospitalisation    earn    strategies    quality    surgery    prototype    severe    17    safer    disease    global    post    rigid    world    carry    directives    42    optimisation    preserves    mobility    medical    invasive    elimination    deformity    commercialisation    deformities    additional    holds    huge    obstructive    cure    chronic    shorter    annual    meeting    capture    rehabilitation    revenues       2022    innovative    market    arthritis    techniques    procedure    introductory    lifetime    significantly    rate    reported    months    complete    compound    solution    surgical    marketing    business    scoliosis    people    share    billion    life    selling    fusion    12    permanently    million    diabetes    model    grow    operative    period    intend    caused    care    spinal       alternative    population    40    physical    engage    plan    lung       arrest    permanent    correction    hypertension    spine    phases    international    treatment    complexity    undergo    restricting    time   

Project "ImplantFreeSpine" data sheet

The following table provides information about the project.

Coordinator
ATC GROUP LIMITED 

Organization address
address: UNIT 17 PERRYWOOD BUSINESS PARK HONEYCROCK LANE SALFORDS
city: REDHILL SURREY
postcode: RH1 5JQ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.atcltd.co.uk/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ATC GROUP LIMITED UK (REDHILL SURREY) coordinator 50˙000.00

Map

 Project objective

Scoliosis affects 2-3% of the world population i.e. about 12 million people in the EU. 20,000 cases of severe scoliosis are reported each year in the EU but less than 3,000 cases ever undergo surgery due to cost and complexity of the surgery. Severe cases of scoliosis are treated by spinal fusion; a major surgical procedure that makes the spine permanently rigid restricting physical activities and permanent arrest of spinal growth. The impact of spinal deformity caused by scoliosis on the quality of life before and after surgery is huge compared with other chronic conditions such as arthritis, chronic obstructive lung disease, diabetes and hypertension. Due to the need for an alternative method for better correction of scoliosis deformities we have developed novel devices and a highly innovative care model involving a safer and significantly less invasive, complete cure which preserves spinal mobility and growth potential. Our solution will result in reduced cost of treatment by over 40% because of shorter hospitalisation, reduced operating time, elimination of additional procedures and lifetime care costs. Spine surgery currently holds a €10.2 billion global market share and is estimated to grow at a compound annual growth rate of 6.9% to reach €17.5 billion by 2022. We aim to capture a market share of 0.1% in 5 years post commercialisation of our project and earn compound revenues of €42.5 million by selling our devices over the same period. In Phase 1 of this project we intend to conduct detailed planning of the testing and design optimisation phases, carry out a market study plan, identify and engage international partners and develop a draft business plan for use upon commercialisation within a period of 6 months. In Phase 2 we will develop an advanced prototype meeting relevant EU and US Medical Devices Directives, demonstrate surgical techniques, rehabilitation strategies, and post-operative procedures and also conduct introductory marketing of our devices.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMPLANTFREESPINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMPLANTFREESPINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More